Study of anxiolytic activity and possible side effects of the dipeptide ligand of the translocator protein TSPO — compound GD-102 in a wide range of doses in behavioral experiments using rats and mice

Background. The dipeptide TSPO ligand, the compound amide N-phenylpropionyl-L-tryptophanyl-L-leucine (GD-102) was designed and synthesized in the Federal research center for innovator and emerging biomedical and pharmaceutical technologies. It was shown that GD-102 possessed anxiolytic and antidepre...

Full description

Saved in:
Bibliographic Details
Main Authors: S. O. Kotel'nikova, O. A. Deeva, V. A. Kraineva, T. A. Gudasheva, T. A. Voronina, V. L. Dorofeev
Format: Article
Language:Russian
Published: LLC “Publisher OKI” 2025-05-01
Series:Фармакокинетика и Фармакодинамика
Subjects:
Online Access:https://www.pharmacokinetica.ru/jour/article/view/447
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850062640165945344
author S. O. Kotel'nikova
O. A. Deeva
V. A. Kraineva
T. A. Gudasheva
T. A. Voronina
V. L. Dorofeev
author_facet S. O. Kotel'nikova
O. A. Deeva
V. A. Kraineva
T. A. Gudasheva
T. A. Voronina
V. L. Dorofeev
author_sort S. O. Kotel'nikova
collection DOAJ
description Background. The dipeptide TSPO ligand, the compound amide N-phenylpropionyl-L-tryptophanyl-L-leucine (GD-102) was designed and synthesized in the Federal research center for innovator and emerging biomedical and pharmaceutical technologies. It was shown that GD-102 possessed anxiolytic and antidepressant-like activity in behavioral experiments using mice.The aim of this work was studying the anxiolytic activity and possible side effects of GD-102 in a wide range of doses from 0.01 to 5.0 mg/kg in experiments using rats and mice.Materials and methods. The pharmacological effects of GD-102 were studied with single intraperitoneal administration. The anxiolytic activity of GD-102 was studied in rats in the elevated plus maze test. The "climbing on the net" test was used to record orientation-exploratory behavior; the muscle relaxant properties were studied in the "rotating rod" and "horizontal bar" tests.Results. It was found that GD-102 at doses of 1.0 and 0.1 mg/kg (once administration), has a pronounced anxiolytic effect in the elevated plus maze test, significantly increasing the time the rats spent in the open arms of the maze and the number of entries into the open arms of the maze. The study of the sedative/activating effects on various behavior models indicated that GD-102 in a wide range of doses (from 0.01 to 5.0 mg/kg) did not affect orientation-exploratory behavior. In the dose range from 0.01 to 5.0 mg/kg, compound GD-102 does not impair the coordination of movements in the rotating rod test and the pull-up reflex on a horizontal bar, which indicates that compound GD-102 have not side effect on muscle relaxantion.Conclusion. The obtained results allow us to conclude that the dipeptide ligand of the TSPO translocator protein, compound GD-102, has a pronounced anxiolytic effect and does not have a sedative or muscle relaxant effect in a wide range of doses, which determines the feasibility of its further expanded preclinical study.
format Article
id doaj-art-5714769100f446498c355d0c652c0793
institution DOAJ
issn 2587-7836
2686-8830
language Russian
publishDate 2025-05-01
publisher LLC “Publisher OKI”
record_format Article
series Фармакокинетика и Фармакодинамика
spelling doaj-art-5714769100f446498c355d0c652c07932025-08-20T02:49:52ZrusLLC “Publisher OKI”Фармакокинетика и Фармакодинамика2587-78362686-88302025-05-0101273410.37489/2587-7836-2025-1-27-34395Study of anxiolytic activity and possible side effects of the dipeptide ligand of the translocator protein TSPO — compound GD-102 in a wide range of doses in behavioral experiments using rats and miceS. O. Kotel'nikova0O. A. Deeva1V. A. Kraineva2T. A. Gudasheva3T. A. Voronina4V. L. Dorofeev5Federal research center for innovator and emerging biomedical and pharmaceutical technologiesFederal research center for innovator and emerging biomedical and pharmaceutical technologiesFederal research center for innovator and emerging biomedical and pharmaceutical technologiesFederal research center for innovator and emerging biomedical and pharmaceutical technologiesFederal research center for innovator and emerging biomedical and pharmaceutical technologiesFederal research center for innovator and emerging biomedical and pharmaceutical technologiesBackground. The dipeptide TSPO ligand, the compound amide N-phenylpropionyl-L-tryptophanyl-L-leucine (GD-102) was designed and synthesized in the Federal research center for innovator and emerging biomedical and pharmaceutical technologies. It was shown that GD-102 possessed anxiolytic and antidepressant-like activity in behavioral experiments using mice.The aim of this work was studying the anxiolytic activity and possible side effects of GD-102 in a wide range of doses from 0.01 to 5.0 mg/kg in experiments using rats and mice.Materials and methods. The pharmacological effects of GD-102 were studied with single intraperitoneal administration. The anxiolytic activity of GD-102 was studied in rats in the elevated plus maze test. The "climbing on the net" test was used to record orientation-exploratory behavior; the muscle relaxant properties were studied in the "rotating rod" and "horizontal bar" tests.Results. It was found that GD-102 at doses of 1.0 and 0.1 mg/kg (once administration), has a pronounced anxiolytic effect in the elevated plus maze test, significantly increasing the time the rats spent in the open arms of the maze and the number of entries into the open arms of the maze. The study of the sedative/activating effects on various behavior models indicated that GD-102 in a wide range of doses (from 0.01 to 5.0 mg/kg) did not affect orientation-exploratory behavior. In the dose range from 0.01 to 5.0 mg/kg, compound GD-102 does not impair the coordination of movements in the rotating rod test and the pull-up reflex on a horizontal bar, which indicates that compound GD-102 have not side effect on muscle relaxantion.Conclusion. The obtained results allow us to conclude that the dipeptide ligand of the TSPO translocator protein, compound GD-102, has a pronounced anxiolytic effect and does not have a sedative or muscle relaxant effect in a wide range of doses, which determines the feasibility of its further expanded preclinical study.https://www.pharmacokinetica.ru/jour/article/view/447tspo ligandsgd-102anxiolytic activitylocomotor activitymyorelaxant effectmicerats
spellingShingle S. O. Kotel'nikova
O. A. Deeva
V. A. Kraineva
T. A. Gudasheva
T. A. Voronina
V. L. Dorofeev
Study of anxiolytic activity and possible side effects of the dipeptide ligand of the translocator protein TSPO — compound GD-102 in a wide range of doses in behavioral experiments using rats and mice
Фармакокинетика и Фармакодинамика
tspo ligands
gd-102
anxiolytic activity
locomotor activity
myorelaxant effect
mice
rats
title Study of anxiolytic activity and possible side effects of the dipeptide ligand of the translocator protein TSPO — compound GD-102 in a wide range of doses in behavioral experiments using rats and mice
title_full Study of anxiolytic activity and possible side effects of the dipeptide ligand of the translocator protein TSPO — compound GD-102 in a wide range of doses in behavioral experiments using rats and mice
title_fullStr Study of anxiolytic activity and possible side effects of the dipeptide ligand of the translocator protein TSPO — compound GD-102 in a wide range of doses in behavioral experiments using rats and mice
title_full_unstemmed Study of anxiolytic activity and possible side effects of the dipeptide ligand of the translocator protein TSPO — compound GD-102 in a wide range of doses in behavioral experiments using rats and mice
title_short Study of anxiolytic activity and possible side effects of the dipeptide ligand of the translocator protein TSPO — compound GD-102 in a wide range of doses in behavioral experiments using rats and mice
title_sort study of anxiolytic activity and possible side effects of the dipeptide ligand of the translocator protein tspo compound gd 102 in a wide range of doses in behavioral experiments using rats and mice
topic tspo ligands
gd-102
anxiolytic activity
locomotor activity
myorelaxant effect
mice
rats
url https://www.pharmacokinetica.ru/jour/article/view/447
work_keys_str_mv AT sokotelnikova studyofanxiolyticactivityandpossiblesideeffectsofthedipeptideligandofthetranslocatorproteintspocompoundgd102inawiderangeofdosesinbehavioralexperimentsusingratsandmice
AT oadeeva studyofanxiolyticactivityandpossiblesideeffectsofthedipeptideligandofthetranslocatorproteintspocompoundgd102inawiderangeofdosesinbehavioralexperimentsusingratsandmice
AT vakraineva studyofanxiolyticactivityandpossiblesideeffectsofthedipeptideligandofthetranslocatorproteintspocompoundgd102inawiderangeofdosesinbehavioralexperimentsusingratsandmice
AT tagudasheva studyofanxiolyticactivityandpossiblesideeffectsofthedipeptideligandofthetranslocatorproteintspocompoundgd102inawiderangeofdosesinbehavioralexperimentsusingratsandmice
AT tavoronina studyofanxiolyticactivityandpossiblesideeffectsofthedipeptideligandofthetranslocatorproteintspocompoundgd102inawiderangeofdosesinbehavioralexperimentsusingratsandmice
AT vldorofeev studyofanxiolyticactivityandpossiblesideeffectsofthedipeptideligandofthetranslocatorproteintspocompoundgd102inawiderangeofdosesinbehavioralexperimentsusingratsandmice